A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial.

Heise, Tim; Tack, Cees J; Cuddihy, Robert; Davidson, Jaime; Gouet, Didier; Liebl, Andreas; Romero, Enrique; Mersebach, Henriette; Dykiel, Patrik; Jorde, Rolf

Heise, Tim; Tack, Cees J; Cuddihy, Robert; Davidson, Jaime; Gouet, Didier; Liebl, Andreas; Romero, Enrique; Mersebach, Henriette; Dykiel, Patrik; Jorde, Rolf.

Affiliation

Heise T; Profil Institut für Stoffwechselforschung, Neuss, Germany. tim.heise@profil-research.de

Diabetes Care ; 34(3): 669-74, 2011 Mar.

Article in En | MEDLINE | ID: mdl-21285389

Subject(s)

Diabetes Mellitus, Type 2/drug therapy; Hypoglycemic Agents/therapeutic use; Insulin/analogs & derivatives; Adolescent; Adult; Aged; Female; Humans; Insulin/therapeutic use; Insulin Glargine; Insulin, Long-Acting; Male; Middle Aged; Treatment Outcome; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Hypoglycemic Agents / Insulin Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Diabetes Care Year: 2011 Document type: Article Affiliation country: Germany Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google